Education
About Us
Working with TipRanks
Follow Us
CareDx (CDNA)
NASDAQ:CDNA
CDNA Stock Chart & Stats
$17.22
$0.67(2.95%)
At close: 4:00 PM EST
$17.22
$0.67(2.95%)
Day’s Range― - ―
52-Week Range$10.96 - $25.95
Previous CloseN/A
Volume177.07K
Average Volume (3M)1.12M
Market Cap
$885.67M
Enterprise Value$614.76M
Total Cash (Recent Filing)$194.22M
Total Debt (Recent Filing)$27.64M
Price to Earnings (P/E)14.4
Beta1.13
Next Earnings
Mar 04, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding51,432,640
10 Day Avg. Volume957,989
30 Day Avg. Volume1,123,784
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.99
Price to Sales (P/S)3.39
P/FCF Ratio35.80
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit2.55
Enterprise Value/Ebitda-35.80
Forecast
1Y Price Target
$22.00Price Target Upside27.76% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Collection ImprovementsImprovements in cash collections and revenue-cycle management are increasing cash inflows from tests and reducing accrual risk, improving cash-flow quality.
Earnings BeatRevenue and profitability results exceeded analyst expectations, with higher-than-forecast revenue and a swing to net income supporting a stronger valuation outlook.
EMR Integration And Growth InitiativesEMR integration with Epic Aura and other growth initiatives are positioned to expand service volumes and commercial reach by 2026, offering a clear driver for future revenue growth.
Bears Say
MolDX Draft LCD UncertaintyThe draft LCD from MolDX creates reimbursement uncertainty that may constrain coverage and pricing for transplant diagnostics until resolution in early 2026.
Prior-period Collection IssuesIssues with prior-period collections and lower-than-expected prior accrual recoveries weigh on reported revenue comparability and complicate cash-flow visibility.
Transplant Volume SoftnessSofter-than-expected kidney transplant volumes have reduced test counts and pressured revenue growth, highlighting demand risk in the core market.
CareDx News
CDNA FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was $10.96 and its highest was $25.95 in the past 12 months.
What is CareDx’s market cap?
CareDx’s market cap is $885.67M.
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is Mar 04, 2026 which is in 51 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Nov 04, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.112.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is <0.01.
How many shares outstanding does CareDx have?
CareDx has 51,432,640 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went up 13.843%.
Which hedge fund is a major shareholder of CareDx?
Currently, no hedge funds are holding shares in CDNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareDx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.00 (27.76% Upside)
$22.00 (27.76% Upside)
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.91%
12-Months-Change
Fundamentals
Return on Equity
24.11%
Trailing 12-Months
Asset Growth
-9.37%
Trailing 12-Months
Company Description
CareDx
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
CDNA Company Deck
CDNA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter with significant revenue growth and operational improvements, including successful product launches and strategic initiatives. However, the overall market conditions for transplant volumes have been flat, and the expected impact from the IOTA program has not yet been realized.View all CDNA earnings summariesCDNA Stock 12 Month Forecast
Average Price Target
$22.00
▲(27.76% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---